Cyxone strengthens its market position through the acquisition of patent portfolio
Today, Cyxone announce that they will acquire the entire family of patents protecting the Company's main candidate T20K, from the Medical University of Vienna. The cost of € 100,930 includes VAT and corresponds to the costs of the patenting process.The cyclotide based lead candidate was licensed in 2015, through the holding company Accequa, to technically verify performance before a full acquisition. In line with Cyxone's requirements, T20K has demonstrated significant beneficial qualities - such as low toxicity and a large interval between the effective dose and the dose that can cause